Get the Finder app 🥳

Connect your accounts & save

How to buy BioNTech shares | US$64.14

Own BioNTech stock in just a few minutes.

Posted

Fact checked
Picture not described
BioNTech (BNTX) is a leading Biotechnology business with stocks listed in the USA. It opened the day at US$77.7, after a previous close of US$66.74. During the day the price has varied from a low of US$62.3 to a high of US$79.38. The latest price was US$64.14 (25-minute delay). BioNTech (BNTX) is listed on the NASDAQ and employs 1400 staff. All prices are listed in US Dollars.

How to buy shares in BioNTech

  1. Compare share trading platforms. To buy shares in a US company from Australia you’ll need to find a trading platform that offers access to US stock markets. If you’re just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for BioNTech. Find the share by name or ticker symbol: BNTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BioNTech reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price of US$64.14, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of BioNTech, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of BioNTech. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Price details for BioNTech (BNTX)

Open $77.7 Previous close $66.74
High $79.38 Change $-2.6
Low $62.3 Change % -3.896%
Close $64.14 Timestamp 1593633600
Volume N/A GMT offset 0

BioNTech stock price

Use our graph to track the performance of BNTX stocks over time.

Share Trading Account Offer

IG Share Trading Offer

USD 0

Standard brokerage - US shares

Share Trading Account Offer

Competitive broker fees on Australian shares, international shares, forex and CFD trading.

  • Brokerage - AU shares: From AUD 5 or 0.05%
  • Brokerage - US shares: USD 0
  • Sign-up process: Instant
  • Support - After hours: Yes
Go to site
More info

Important: Share trading carries risk of capital loss.

Promoted

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Data indicated here is updated regularly
Name Product Standard brokerage fee Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
IG Share Trading
AUD 8 or
0.1%
USD 0
AUD 50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares
Global shares
Forex
CFDs
Margin trading
Active trader brokerage discount: AUD 5 or 0.05% if you've placed 3 trades or more in the prior month.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, forex and CFDs, plus get access to 24-hour customer support.
Bell Direct Share Trading
AUD 15 or
0.1%
N/A
No
N/A
ASX shares
mFunds
Invest in Australian shares, options and managed funds from the one account with no inactivity fee.
Bell Direct offers a one-second placement guarantee on market-to-limit ASX orders or your trade is free, plus enjoy extensive free research reports from top financial experts.
eToro Share Trading (US stocks)
N/A
USD 0
USD 10 per month if there’s been no login for 12 months
0.50%
Forex
CFDs
US shares
Zero brokerage share trading on US stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and forex from the one account.
CMC Markets Stockbroking
AUD 11 or
0.1%
USD 19.95
AUD 15 per month if you make no trades in that period
0.60%
ASX shares
Global shares
Forex
CFDs
Margin trading
Options trading
mFunds
Access a broad range of investment products from Australia and overseas.
Invest in managed funds, trade shares, warrants, options and CFDs listed across the ASX, SSX and Chi-X, and other major global exchanges, including US, Canada and UK markets.
ANZ Share Investing
AUD 19.95
AUD 59
No
0.60%
ASX shares
Global shares
Margin trading
Options trading
Earn 1 Qantas Point per AU$3 spent on brokerage fees on certain instruments.
Access Morningstar reports, company announcements and and live pricing via ANZ’s share investing platform. Available for desktop and mobile.
Westpac Online Investing Account
AUD 19.95 or
0.11%
USD 19.95
AUD 63.50 per year on the global markets account
0.60%
ASX shares
Global shares
Options trading
US shares
loading

Compare up to 4 providers

Should I buy BioNTech shares?

This is not a recommendation, it represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

BioNTech company summary

Information last updated 2020-06-28.

BioNTech (BNTX) is a leading Biotechnology business based in the USA. BioNTech (BNTX) is listed on the NASDAQ and employs 1400 staff.

Profile

Industry Biotechnology Currency symbol $
Code BNTX Country name USA
Type Common Stock Country ISO US
Name BioNTech SE ISIN N/A
Exchange NASDAQ CUSIP N/A
Currency code USD Sector Healthcare
Currency name US Dollar Full-time employees 1400

Detailed company information

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has a collaboration with Pfizer Inc. to develop vaccines for the coronavirus using its mRNA-based drug development platform; and development and commercialization collaboration with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to advance a vaccine candidate BNT162 for the prevention of COVID-19 infections. The company was founded in 2008 and is headquartered in Mainz, Germany.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

Related Posts

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Ask a question
Go to site